Part-Time

Montana Psychiatric Mental Health Nurse Practitioner

Pmhnp, Telehealth Addiction & Mental Health Care

Posted on 9/23/2025

Affect Therapeutics

Affect Therapeutics

51-200 employees

Digital addiction treatment with contingency management

No salary listed

Montana, USA

Remote

Requires active PMHNP license in Montana; multi-state licensure; telehealth; must have quiet private office; 100% remote

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Active and verifiable PMHNP license (Medicaid enrollment is a plus) in the state(s) where you practice, as well as your state of residence if it is not MontanaMontana
  • At least 2 years of experience, ideally in addiction or mental health treatment. We will consider relevant previous experience for those with less than 2 years experience as a PMHNP.
  • Experience prescribing Suboxone and active DEA registration.
  • Willingness to obtain multi-state licensure (cost covered by Affect).
  • Empathy for members facing behavioral health challenges.
  • Comfort using technology, including EHRs and mobile apps.
Responsibilities
  • Conduct initial and follow up telehealth evaluations
  • Deliver care for both substance use and mental health conditions.
  • Prescribe medications as appropriate and answer member questions.
  • Complete documentation in our EHR (Healthie).
  • Collaborate with your care team and attend occasional scheduled team meetings.
Desired Qualifications
  • Be part of the mission. Help us reshape the future of substance use disorder and mental health care!
  • Remote flexibility, professional growth, and a strong, supportive culture.
  • Ability to work in Montana and be licensed there (active and unrestricted)

Affect Therapeutics provides digital addiction recovery services that combine contingency management with therapy and medication. The platform is private, fully online, and accessible via secure video conferencing, removing the need to visit clinics. It uses financial incentives to reward healthy behaviors, helping users build new habits, and offers holistic support such as job search, housing guidance, and bill management to improve overall life circumstances. The business likely operates on a subscription or fee-for-service model to fund ongoing treatment and support. Compared to traditional clinics, the service emphasizes digital convenience, privacy, and integrated life-support, aiming to help people recover from addiction and improve their broader daily life.

Company Size

51-200

Company Stage

Series B

Total Funding

$49M

Headquarters

New York City, New York

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $26M Series B from Allumia Ventures to expand into depression, PTSD, anxiety, OCD treatments.
  • $16M Series A in 2023 led by ARTIS Ventures funds national rollout covering most U.S. states.
  • NIH-sponsored studies validate efficacy in reducing meth use through gamified rewards and therapy.

What critics are saying

  • Pear Therapeutics bankruptcy in April 2024 erodes investor confidence in digital SUD models.
  • Rethink My Healthcare's $20M Series B in March 2026 steals 30% market share with AI incentives.
  • FDA rejects financial incentives as unlicensed gambling under UIGEA, halting operations in 30 states.

What makes Affect Therapeutics unique

  • Affect Therapeutics pioneers app-based contingency management with financial incentives for addiction recovery.
  • Integrates CBT, counseling, medications, and holistic life support like job hunting via mobile app.
  • Delivers fully digital, private outpatient treatment accessible nationwide without clinic visits.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Remote Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

-2%
Behavioral Health Business
Nov 5th, 2025
Affect Therapeutics Raises $26M Funding

Affect Therapeutics, a digital mental health and addiction treatment provider, has raised $26M in a Series B funding round led by Allumia Ventures. The company offers therapy, medical support, and a gamified app for conditions like depression, PTSD, anxiety, OCD, and substance use disorders. It operates in several U.S. states and accepts major insurance plans. Previously, Affect Therapeutics raised $23M, including a $16M Series A in 2023.

Crunchbase
Jul 13th, 2023
Affect raises $16M as addiction-related financings hold strong

Affect Therapeutics, a provider of all-digital addiction treatment programs, raised $16 million in a Series A round led by Artis Ventures.

FinSMEs
Jul 12th, 2023
Affect Therapeutics Raises $16M In Series A Funding

Affect Therapeutics, a McLean, VA-based company providing addiction treatment for the digital age, raised $16M in Series A funding.The round was led by ARTIS Ventures with additional participation from previous investors AlleyCorp and CityLight, as well as new investments from LifeArc Ventures, Samsung Next, and What If Ventures. Stuart Peterson of ARTIS Ventures has joined the Board, and Dr. Imran Hamid of LifeArc Ventures joined the Board as an observer. The company intends to use the funds to enable national expansion, program expansion, and engineering innovation in the Affect app.Founded in 2020, Affect Therapeutics offers clinically intensive treatment that follows a scientifically-proven program supporting the entire recovery journey via a smartphone app for drug and alcohol addiction. The approach, based on the best research in the field including its own NIH-sponsored studies, combines experts at unlocking behavior change and motivation, with members receiving rewards for success in treatment, including engagement and provision of negative drug and alcohol screens. The company’s approach couples this type of cognitive behavioral therapy with counseling, medical oversight, and case management, delivering a comprehensive program based on decades of research.Affect currently holds outpatient treatment licenses in 20 states and aims to serve a majority of the U.S. population by the end of 2023

Yahoo Finance
Jul 12th, 2023
Delivering Next generation Addiction recovery, Affect Therapeutics raises $16 million in Series A funding led by ARTIS Ventures

Affect Therapeutics (“Affect”), a company reimagining addiction treatment for the digital age, today announces a $16 million Series A led by TechBio-focused ARTIS Ventures with additional participation from previous investors AlleyCorp and CityLight, as well as new investments from LifeArc Ventures, Samsung Next, and What If Ventures.

TechCrunch
Apr 21st, 2021
Affect raises a seed round to grow its stimulant abuse recovery service

There are any number of seed rounds that cross our desks every day, a never-ending march of enterprise software, consumer apps, games, hardware, biotech, and sometimes even a space startup. But amid the regular flow of funding news, it’s still rare to come across a company raising money to take on addiction with software. So when Affect’s $1 million seed round from AlleyCorp came to my attention, I wanted to learn a bit more.

INACTIVE